FORM 4
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Check this box if no longer
subject to Section 16. Form 4
or Form 5 obligations may
continue. See Instruction 1(b)
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public UtilityHolding Company Act of 1935 of
Section 30(f) of the Investment Company Act of 1940
<TABLE>
<S> <C>
- ------------------------------------------------------------------ -----------------------------------------------------------------
2. Issuer Name and Ticker or Trading Symbol
Name and Address of Reporting Person LifePoint, Inc - LFPT
Masterson Linda H.
____________________________________________________________
(Last) (First) (Middle)
10400 Trademark Street
____________________________________________________________
(Street)
Rancho Cucamonga, CA 91730
____________________________________________________________
City (State) (Zip)
- ------------------------------------------------------------------ -----------------------------------------------------------------
- ------------------------------------------------------------------ ------------------------- ---------------------------------------
<C> <C>
3. IRS or Social 4. Statement for Month/Year
Security Number of
Reporting Person 10/99
(Voluntary)
###-##-####
- ------------------------------------------------------------------ ------------------------- ---------------------------------------
- ------------------------------------------------------------------ ------------------------- ---------------------------------------
<C>
5. If Amendment, Date of Original
(Month/Year)
- ------------------------------------------------------------------ ------------------------- ---------------------------------------
- ------------------------------------------------------------------ -----------------------------------------------------------------
<C>
6. Relationship of Reporting Person to Issuer
(Check if Applicable)
X Director ___ 10% Owner
X Officer ___ Other (specify below)
(give title below)
President and CEO
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
- --------------------------------------------------------- -----------------------------------------------------------------------
- --------------------------------------------------------- ------------------- ------------------ --------------------------------
<S> <C> <C> <C>
1. Title of Security 2. Transaction 3. Transaction 4. Securities Acquired (A) or
(Instr. 3) Date Code Disposed of (D) (Instr. 3, 4,
(Month/Day/Year) (Instr. 8) and 5)
- --------------------------------------------------------- ------------------- ------------------ --------------------------------
- --------------------------------------------------------- ------------------- ---------- ------- ----------- --------- ----------
Code V Amount (A) or Price
(D)
- --------------------------------------------------------- ------------------- ---------- ------- ----------- --------- ----------
- --------------------------------------------------------- ------------------- ---------- ------- ----------- --------- ----------
None
- --------------------------------------------------------- ------------------- ---------- ------- ----------- --------- ----------
- --------------------------------------------------------- ------------------- ---------- ------- ----------- --------- ----------
<C> <C> <C>
- --------------- ----------- ---------------
- --------------- ----------- ---------------
5. Amount of 6. 7. Nature of
Securities Owner-ship Indirect
Beneficially Form: Beneficially
Owned at End Direct Ownership
of Month (D) or (Instr. 4)
(Instr. 3 and Indirect
4) (I)
(Instr. 4)
- --------------- ----------- ---------------
- --------------- ----------- ---------------
- --------------- ----------- ---------------
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
<TABLE>
<CAPTION>
<PAGE>
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
<S> <C> <C> <C> <C> <C>
- ---------------------------- ------------- -------------- -------------- --------------- -----------------
1. Title of Derivative 2. Conver- 3. 4. 5. Number of 6. Date
Security (Instr. 3) sion or Transaction Transaction Derivation Exercisable and
Exercisable Date Code (Instr.8 Securities Expiration Date
Price of (Month/Day/Year Acquired (A) (Month/Date/Year)
Derivative or Disposed
Security of (D)
(Instr. 3,4,
and 5)
- ---------------------------- ------------- -------------- -------------- --------------- -----------------
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
Code V (A) (D) Date Expiration
Exercis- Date
able
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
Stock Option $1.68 10/10/99 A 120,000 0 (1) 10/9/09
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
Common Stock Purchase $1.72 10/10/99 A 1 0 (2) (3)
Warrant
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
Common Stock Purchase $1.72 10/10/99 A 1 0 (4) (5)
Warrant
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
Common Stock Purchase $1.72 10/10/99 A 1 0 (6) (7)
Warrant
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
Common Stock Purchase $1.72 10/10/99 A 1 0 (8) (9)
Warrant
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
Common Stock Purchase $1.72 10/10/99 A 1 0 (10) (11)
Warrant
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
- ---------------------------- ------------- -------------- ------ ------- -------- ------ -------- --------
<S> <C> <C> <C> <C>
- ------------------------ ------------- ------------- ----------- -----------
7. Title and Amount of 8. Price of 9. Number 10. 11.
Underlying Securities Derivative of Ownership Nature of
(Instr. 3 and 4) Security Derivative Form of Indirect
(Instr. 5) Securities Derivative Beneficial
Beneficially Security: Ownership
Owned at Direct (Instr. 4)
end of (D) or
month Indirect
(Instr. 4) (I)
(Instr. 4)
- ------------------------ ------------- ------------- ----------- -----------
- ----------- ------------ ------------- ------------- ----------- -----------
Title Amount or
Number of
Shares
- ----------- ------------ ------------- ------------- ----------- -----------
- ----------- ------------ ------------- ------------- ----------- -----------
Common 120,000 0 870,000 D N/A
Stock
- ----------- ------------ ------------- ------------- ----------- -----------
- ----------- ------------ ------------- ------------- ----------- -----------
Common 500,000 0 1,370,000 D N/A
Stock
- ----------- ------------ ------------- ------------- ----------- -----------
- ----------- ------------ ------------- ------------- ----------- -----------
Common 500,000 0 1,870,000 D N/A
Stock
- ----------- ------------ ------------- ------------- ----------- -----------
- ----------- ------------ ------------- ------------- ----------- -----------
Common 500,000 0 2,370,000 D N/A
Stock
- ----------- ------------ ------------- ------------- ----------- -----------
- ----------- ------------ ------------- ------------- ----------- -----------
Common 500,000 0 2,870,000 D N/A
Stock
- ----------- ------------ ------------- ------------- ----------- -----------
- ----------- ------------ ------------- ------------- ----------- -----------
Common 500,000 0 3,370,000 D N/A
Stock
- ----------- ------------ ------------- ------------- ----------- -----------
- ----------- ------------ ------------- ------------- ----------- -----------
- ----------- ------------ ------------- ------------- ----------- -----------
</TABLE>
<PAGE>
Explanation of Responses:
(1) Option becomes exercisable as to 30,000 shares on 10/10/00, and as to 2,500
shares on the 10th of each month for 36 months thereafter.
(2) Warrant becomes exercisable only if the Issuer enters into a strategic
partnership arrangement prior to October 10, 2001 and the reporting person
is still CEO of the Issuer at such time.
(3) The earlier of the 5th anniversary of the day before the day on which a
strategic partnership agreement is executed, or October 9, 2006.
(4) Warrant becomes exercisable only if the warrant in note #2 becomes
exercisable and the Issuer executed, prior to October 10, 2001, a
definitive agreement with a second strategic partner and the reporting
person is still CEO of Issuer at such time.
(5) The earlier of the 5th anniversary of the day before the day on which the
second strategic partnership is executed or October 9, 2006.
(6) Warrant becomes exercisable only if Issuer secures financing of at least
$4,500,000 prior to October 10, 2000 and the reporting person is still CEO
at such time.
(7) The earlier of the day before the 5th anniversary of the closing date of
the financing (see note #6) or October 9, 2005.
(8) Warrant becomes exercisable only if the Issuer completes certain clinical
trails before October 1, 2000 and the reporting person is CEO of Issuer on
the date such trials are completed.
(9) The earlier of the day before the 5th anniversary of the day on which
certain clinical trails are completed or September 30, 2005.
(10) Warrant becomes exercisable only if the Issuer derives revenues of $100,000
from sales of its saliva based testing product prior to January 1, 2001 and
the reporting person is CEO of Issuer on the date sales are consummated.
(11) The earlier of the day before the 5th Anniversary of the day on which sales
for $100,000 of Issuer's product are consummated or December 31, 2005.
/s/ Linda H. Masterson 11/5/99
---------------------------------------------
Signature of Reporting Person Date
**Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If
space provided is insufficient, See Instruction 6 for procedure.
